Results of a Phase II Multicenter Trial of Single-Agent Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkin's Lymphoma

Venkatesh, Hemachandra; Bella, Nicholas Di; Flynn, Thomas P.; Vellek, Mark; Boehm, Kristi A.; Asmar, Lina

doi:10.3816/clm.2004.n.017

Cited by 47 publications

(34 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Responses that were associated with modest durability have been reported in monotherapy case series evaluating gemcitabine, vinorelbine, or vinblastine. [26][27][28][29][30][31] Combination regimens (e.g., gemcitabine, vinorelbine, and pegylated liposomal doxorubicin) have shown somewhat higher response rates but have been associated with substantial toxic effects. 32 However, complete remissions are rare in patients with drug-refractory Hodgkin's lymphoma or systemic ALCL, especially in those treated with single agents.…”

Section: Discussionmentioning

confidence: 99%

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

et al. 2010

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

et al. 2010

View full text Add to dashboard Cite

“…For those patients with cHL relapsing after ASCT and who have received brentuximab, there are a number of options for treatment outlined in Table 1, [37][38][39][40][41][42][43] Table 2, [44][45][46][47][48][49][50][51][52][53][54][55][56][57] and Table 3 28-33, [58][59][60][61] . Treatment decisions should be based on the long-term goals of therapy; for example, prolonged disease control vs achievement of best response prior to allogeneic SCT, extent and location of disease, symptoms, patient comorbidities and age, and patient preference.…”

Section: Treatment Options For Patients Relapsing After Asctmentioning

confidence: 99%

“…[37][38][39][40][41][42][43] Santoro et al reported an ORR of 39% and a median duration of response of 6.7 months in relapsed/refractory cHL patients treated with gemcitabine 1250 mg/m 2 on days 1, 8, and 15 of a 28-day cycle. 38 In a study by Venkatesh et al, 5 of 16 evaluable patients with prior ASCT achieved a PR with gemcitabine, with a median PFS of 6.4 months.…”

Section: Treatment Options For Patients Relapsing After Asctmentioning

confidence: 99%

How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant

Alinari

Blum

2016

Blood

View full text Add to dashboard Cite

Despite the success of standard front-line chemotherapy for classical Hodgkin lymphoma (cHL), a subset of these patients, particularly those with poor prognostic factors at diagnosis (including the presence of B symptoms, bulky disease, advanced stage, or extranodal disease), relapse. For those patients who relapse following autologous stem cell transplant (SCT), multiple treatment options are available, including single-agent chemotherapy, combination chemotherapy strategies, radiotherapy, the immunoconjugate brentuximab, checkpoint inhibitors nivolumab and pembrolizumab, lenalidomide, everolimus, or observation in selected patients. In patients with an available donor, allogeneic SCT may also be considered. With numerous treatment options available, we advocate for a tailored therapeutic approach for patients with relapsed cHL guided by patient-specific characteristics including age, comorbidities, sites of disease (nodal or organ), previous chemosensitivity, and goals of treatment (long-term disease control vs allogeneic SCT).

show abstract

“…with Vinorelbine). 8,9 Favorable toxicity profile and significant clinical antitumor activity were observed in heavily pre-treated HL patients, with overall response rates (ORR) up to 70% when used in combination regimens. 10,11 On the other hand, the duration of response is limited stressing the need to develop novel therapeutic strategies or to use this agent as a bridge rel/ref HL patient into more definitive treatments (i.e.…”

Section: Systemic Chemotherapymentioning

confidence: 99%